Versant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$124K Buy
737
+174
+31% +$25.8K 0.01% 814
2026
Q1
$74.2K Buy
563
+42
+8% +$5.57K 0.01% 1019
2025
Q4
$73.9K Buy
521
+3
+0.6% +$435 0.01% 891
2025
Q3
$72.7K Buy
518
+1
+0.2% +$135 0.01% 859
2025
Q2
$65K Buy
517
+108
+26% +$12.4K 0.01% 849
2025
Q1
$45.2K Buy
409
+328
+405% +$41.6K 0.01% 908
2024
Q4
$11.1K Buy
81
+39
+93% +$4.82K ﹤0.01% 1344
2024
Q3
$4.84K Sell
42
-14
-25% -$1.92K ﹤0.01% 1306
2024
Q2
$7.71K Buy
56
+49
+700% +$6.72K ﹤0.01% 1079
2024
Q1
$965 Hold
7
﹤0.01% 1552
2023
Q4
$922 Buy
7
+3
+75% +$345 ﹤0.01% 1536
2023
Q3
$450 Sell
4
-5
-56% -$527 ﹤0.01% 1712
2023
Q2
$849 Buy
9
+5
+125% +$489 ﹤0.01% 1660
2023
Q1
$397 Sell
4
-7
-64% -$728 ﹤0.01% 1621
2022
Q4
$1.31K Hold
11
﹤0.01% 1243
2022
Q3
$1K Hold
11
﹤0.01% 1296
2022
Q2
$1K Hold
11
﹤0.01% 1317
2022
Q1
$1K Buy
+11
New +$932 ﹤0.01% 1330
2021
Q3
Sell
-3
Closed 1541
2021
Q2
$0 Buy
+3
New +$288 ﹤0.01% 1544

Other funds holding NBIX